Role of biOsimilaRs in Therapeutic Management of Anemia Following Chemotherapy in HEmatology and Oncology; A Prospective, Observational, Non-interventional Study
Role of biOsimilaRs in Therapeutic Management of Anemia Following Chemotherapy in HEmatology and Oncology; A Prospective, Observational, Non-interventional Study
The main aim of this study is to observe correction of the hemoglobin level in the patients under chemotherapy, treated with epoetin alfa biosimilar and presenting with a solid tumor or a lymphoma or a myeloma.
This is a non-interventional, descriptive, national, multi-site, longitudinal and prospective observational study with adults patients who are suffering from cancer or malignant blood disease and whose chemotherapy treatment has induced symptomatic anemia and being treated with biosimilar of epoetin to correct haemoglobin levels.
Inclusion Criteria:
Patients of more than 18 years of age
Patients presenting with anemia following chemotherapy
Patients suffer from solid tumours, malignant hemopathies, lymphomas or myelomas and presenting with anemia following chemotherapy
-- The patients may be included regardless of their chemotherapy cycle (from the first cycle until the last cycle)
Patients eligible for epoetin alfa biosimilar treatment
Exclusion Criteria:
Chalon/saonne, 71321, France
Cherbourg-octeville, 50100, France
Fryming Merle BACH, 57800, France
Mareuil LES MAUX, 77100, France
Monaco, 98012, France
Nantes Saint Herblain, 44805, France
Nogent/Marne, 94130, France
Villefranche/saone, 69655, France